ClinicalTrials.gg
RecruitingNCT07555314Midline LidUpdated Aug 25, 2026

Outpatient Midline Catheter in Patients Receiveing Lidocaine Infusion Series.

An observational study in Midline Catheter, Lidocaine Infusion and Chronic Pain, sponsored by Medical University of Warsaw. Recruiting at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-25.

Sponsored by Medical University of Warsaw · Observational

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Chronic Pain with a site in Poland — 5 open to participants now, 5 under way, none of them phase 3. Chronic Pain · Poland.

Started
2026
with 1 other
Observational
5 of 21
3 open now
Registered
19th of 21
by date
Lead sponsor
3 of 21
Medical University of Warsaw

Among the 21 studies in Chronic Pain with a site in Poland, this one is one of 2 that started in 2026, is one of 5 observational ones, and was the 19th registered.

Chronic Pain

3,228 studies on the registry are indexed under Chronic Pain; 729 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

5 of the 21 studies in Chronic Pain with a site in Poland are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Chronic Pain with a site in Poland, or all of them as a file.
02

Study summary

This study will assess the efficacy, safety and practicality of using midline catheters for repeated intravenous lidocaine infusions in an outpatient pain management setting. Adult patients requiring serial lidocaine infusions for chronic pain will be enrolled and receive treatment through midline catheters over ten sessions.

The study will investigate if the midline catheters are a safe and effective option for delivering repeated lidocaine infusions in the outpatient setting, offering a balance between ease of placement, acceptable complication risk and good patients' comfort.

03

Conditions studied

  • Midline Catheter
  • Lidocaine Infusion
  • Chronic Pain
  • Outpatient

Browse trials for

Keywords

  • midline catheter
  • lidocaine infusion
  • chronic pain
  • outpatient
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Our study population is patients qualified for daily lidocaine infusion therapy for chronic pain. Patients are planned to receive an infusion daily for 10 days with 2 days weekend pause. The total therapy time is planned for 12 days.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients qualified for lidocaine infusion therapy due to the chronic pain
  • Able to provide consent
  • ≥18 years of age

Exclusion criteria

Exclusion Criteria:

  • Lack of patient consent
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Target follow-up
10 Days
Patient registry
Yes

Groups and cohorts

  • Outpatient midline catheter

    Patients who receive a midline catheter for lidocaine infusion daily for ten days with two days weekend pause.

06

What researchers measure

Primary outcomes

  1. Successful lidocaine infusion therapy without the need for additional venous access

    Percentage of patients who received a daily lidocaine infusion for 10 days with a 2-day pause in an outpatient setting who did not require additional venous access.

    Time frame: 12 days (from midline insertion to the end of the therapy)

Secondary outcomes

  1. Midline Catheter Maintenance Duration

    The total duration (in days) that each patient maintains a functional midline catheter without premature removal.

    Time frame: 12 days (from midline insertion to the end of the therapy)

  2. Number of Participants with Premature Catheter Removal and Reasons

    The primary reason for premature catheter removal will be documented, including: occlusion, inadvertent removal, extravasation, suspected infection, confirmed infection, thrombosis, catheter malfunction, phlebitis, or removal at the patient's request.

    Time frame: 12 days (from midline insertion to the end of the therapy)

  3. A-DIVA scale score

    A scale used for the assessment of predicted difficulties in securing difficult intravenous access.

    Time frame: The onset of therapy

  4. Patient's satisfaction score

    Patient satisfaction scores measured on a 0-10 scale

    Time frame: 12 days (from midline insertion to the end of the therapy)

  5. Number of catheter leakage events

    Catheter leakage events is defined as leakage of blood or fluids from the puncture site.

    Time frame: 12 days (from midline insertion to the end of the therapy)

  6. Number of patients with phlebitis

    Phlebitis is defined as infiltration/swelling or pain around the insertion site with medication or fluid administration

    Time frame: 12 days (from midline insertion to the end of the therapy)

  7. Total number of upper extremity deep venous thrombosis events

    This is defined as symptomatic or asymptomatic DVT, verified by ultrasound or computed tomography. The total number of upper extremity DVT events will be recorded by study arm.

    Time frame: 12 days (from midline insertion to the end of the therapy)

  8. Number of patients who requested catheter removal

    The number of patients who requested catheter removal due to discomfort or other reasons.

    Time frame: 12 days (from midline insertion to the end of the therapy)

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Dec 2027, 20 months after the start.

Of 336 non-industry observational studies under Chronic Pain, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 56. This study's planned 20 months is below that.

Counting every sponsor, half of 362 studies reached it within 24 months; a quarter within 12 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2026
First posted
Apr 29, 2026
StartActual
Apr 20, 2026
Primary completionEst.
Dec 30, 2027
CompletionEst.
Jun 1, 2028
Last update
Aug 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07555314
Responsible party
Sponsor
First posted
Apr 29, 2026
Start date
Apr 20, 2026
Primary completion
Dec 30, 2027 (estimated)
Completion
Jun 1, 2028 (estimated)
Last update
Aug 25, 2026

Study contacts

Piotr Mieszczański, MD
Contact
piotr.mieszczanski@wum.edu.pl
+48225021721

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion